CHANTILLY, Va., Oct. 29 /PRNewswire/ -- Dynex Technologies, a Magellan Biosciences company, announced that it will feature powerful clinical- diagnostic systems in the North American Pavilion (Hall 3, Stand D45-6) at Medica 2007, in Duesseldorf, Germany. The company's DS2(R) automated two-plate immunoassay processing system delivers accurate, reliable results to improve health outcomes, yet it is easy to use for even novice lab technicians. In addition, Dynex sister company, ESA Biosciences, will demonstrate its LeadCare(R) II point-of-care system developed to screen children for lead poisoning. The system delivers quantitative blood-lead results, equivalent to those reported by reference laboratories, with only two drops of blood in just three minutes.
Dynex sells the DS2 through ELISA kit manufacturers around the world to meet the needs of labs that don't have the throughput needs to justify large- scale systems on the market. Designed with full walk-away capability, the DS2 represents a major leap forward in electro-mechanics and software design. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power in the smallest footprint available. The system quickly and easily processes two 96-well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics. An open system, the DS2 delivers sample-in/results-out automation of virtually any ELISA microplate assay. Feature-rich and groundbreaking in its process simulation and ease of use, the DS-Matrix(TM) software allows any lab technician to use the DS2 with minimal training, so labs new to automation can rapidly integrate the system with confidence to begin delivering better, more-reliable results.
Dynex will also demonstrate its four-plate DSX(R) automated ELISA processing system, a flexible, open system with full walk-away capability -- now the standard worldwide for medium-throughput labs.
Recent headlines about lead contamination in toys, bibs, and lipstick are spurring unprecedented interest in blood-lead testing, with good reason: early identification of elevated lead levels is key to mitigating its potentially devastating effects. LeadCare II makes pediatric lead testing easy. With a simple finger-stick, and in just three minutes, parents can know their child's blood-lead level, instead of waiting days or weeks for lab results and follow- up appointments. Healthcare providers can take immediate action if necessary, and provide peace of mind when it's not.
About Dynex Technologies
A Magellan Biosciences company, Dynex Technologies is the innovator in automated and semi-automated technologies for microplate analysis. From walk- away ELISA processing stations like its powerful, two-plate DS2 for low- throughput labs to the renowned four-plate DSX -- Dynex designs each of its products to meet the rigorous demands of scientists in clinical, biomedical, and pharmaceutical-development applications. For more information, visit www.dynextechnologies.com.
About ESA Biosciences
ESA Biosciences, Inc. enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. ESA is a wholly owned subsidiary of Magellan Biosciences, Inc. For more information, e-mail firstname.lastname@example.org, or visit www.esainc.com.
About Magellan Biosciences
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use the company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness -- from disease pathology to biomarker identification. Magellan designs all its systems, sensors, and consumables to deliver better, more- reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures -- innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems. For more information, visit www.magellanbio.com.
CONTACT: Caroline Grossman of Magellan Biosciences, +1-781-771-5579,
Web site: http://www.magellanbio.com/